YTHDF2 regulates the adriamycin (ADM) resistance in NKTCL by modulating the m6A modification of SLC16A9
our study provides direct evidence that YTHDF2 modulates ADM resistance in NKTCL by regulating the m6A modification of SLC16A9. Targeting the YTHDF2-m6A-SLC16A9 axis may offer a novel therapeutic strategy to overcome chemotherapy resistance in NKTCL.
Authors
- Siyu Qian (ORCID: https://orcid.org/0000-0002-4877-4537)
- Qingjiang Chen
- Yue Zhang (ORCID: https://orcid.org/0000-0003-3568-0395)
- Meng‐Qiu Dong (ORCID: https://orcid.org/0000-0002-6094-1182)
- Xueyi Sun
- Mingzhi Zhang
- Qing Yang (ORCID: https://orcid.org/0000-0002-2048-4087)
- Shaoxuan Wu
- Zhenzhen Yang (ORCID: https://orcid.org/0000-0003-3270-5411)
- Xudong Zhang (ORCID: https://orcid.org/0009-0002-8631-3632)
- Zeyuan Wang (ORCID: https://orcid.org/0000-0003-0186-1710)
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1016/j.tranon.2025.102448
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81